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Abstract
Background: Persons in addiction treatment are likely to experience and/or witness drug overdoses following
treatment and thus could benefit from overdose education and naloxone distribution (OEND) programs. Diverting
individuals from the criminal justice system to addiction treatment represents one treatment engagement pathway,
yet OEND needs among these individuals have not been fully described.
Methods: We characterized justice involvement patterns among 514 people who use opioids (PWUO) participating
in a criminal justice diversion addiction treatment program during 2014–2016 using a gender-stratified latent class
analysis. We described prevalence and correlates of naloxone knowledge using quasi-Poisson regression models
with robust standard errors.
Results: Only 56% of participants correctly identified naloxone as an opioid overdose treatment despite that 68%
had experienced an overdose and 79% had witnessed another person overdose. We identified two latent justice
involvement classes: low involvement (20.3% of men, 46.5% of women), characterized by older age at first arrest,
more past-year arrests, and less time incarcerated; and high involvement (79.7% of men, 53.5% of women),
characterized by younger age at first arrest and more lifetime arrests and time incarcerated. Justice involvement
was not associated with naloxone knowledge. Male participants who had personally overdosed more commonly
identified naloxone as an overdose treatment after adjustment for age, race, education level, housing status, heroin
use, and injection drug use (prevalence ratio [95% confidence interval]: men 1.5 [1.1–2.0]).
Conclusions: All PWUO in criminal justice diversion programs could benefit from OEND given the high propensity to
experience and witness overdoses and low naloxone knowledge across justice involvement backgrounds and genders.
Keywords: Opioids, Overdose, Naloxone, Addiction treatment, Criminal justice system involvement, Latent class
analysis
Background
Mortality from opioid overdose quadrupled from 1999
to 2016 in the United States (US) [1, 2]. To reduce over-
dose mortality, there is a critical need for overdose edu-
cation and naloxone distribution (OEND) programs to
identify, engage, and train people who use opioids
(PWUO), as they are both potential overdose victims
and bystanders who could respond [3–5]. OEND pro-
grams train potential overdose bystanders to identify
and respond to an opioid overdose and equip partici-
pants with naloxone, an opioid antagonist that reverses
the respiratory depression caused by high doses of opi-
oids [6, 7]. Many also provide information about Good
Samaritan Laws, which protect persons present at an
overdose from legal prosecution for illegal activities dis-
covered when they call 911 [7]. Naloxone distribution to
PWUO is cost-effective, especially when combined with
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addiction treatment, and reduces opioid overdose mor-
tality [8–10]. However, as highlighted recently by the US
Surgeon General [11], there remains an urgent need to
maximize the number of PWUO who are well-
positioned to respond to an overdose or benefit from re-
ceipt of naloxone.
OEND programs are increasingly incorporated into
addiction treatment services, jails, and prisons given the
high prevalence of PWUO in these settings and the ele-
vation in overdose risk following addiction treatment
and incarceration [4, 12–14]. Mortality among PWUO is
up to 21-fold higher after addiction treatment and up to
129-fold higher in the weeks after incarceration relative
to the general population [12, 15]. The elevated risk of
overdose during these periods is due to a loss of physio-
logic tolerance to opioids during periods of incarceration
or treatment [16]. A lack of access to medication-
assisted treatments and social services (e.g., housing)
may further contribute to a return to opioid use and
subsequent heightened overdose risk [12]. Pre-release
naloxone distribution in corrections institutions has re-
duced population-level overdose risk [17] and may have
benefits for witnessed overdose [18].
The US Surgeon General recently called for an im-
provement in the pre- and post-release addiction treat-
ment services available to incarcerated PWUO and for a
“transition to a less punitive and more health-focused
approach” [11]. Herein, we examine one less punitive ap-
proach in which the addiction treatment and criminal
justice system settings intersect: justice diversion addic-
tion treatment programs, which provide PWUO facing
legal prosecution with addiction treatment to reduce
sentences or avoid criminal charges [13, 19, 20]. PWUO
are referred to justice diversion programs by law en-
forcement, drug courts, the correctional system, or
through parole or probationary boards [19, 21–25]. How
best to tailor OEND programs to minimize post-
treatment overdose risk among clients of justice diver-
sion addiction treatments has not been thoroughly
examined.
This study aims to inform OEND planning using a
sample of 514 PWUO in a residential justice diversion
addiction treatment program in Michigan. First, we
characterize justice involvement preceding diversion
(e.g., arrest history, age at first arrest, time incarcerated),
history of overdose experiences and witnessed overdose,
and naloxone knowledge among PWUO in a justice di-
version addiction treatment program. We evaluate these
separately by gender to account for potential differences
in justice involvement for men and women. Second, we
evaluate whether justice involvement history is associ-
ated with experiencing or witnessing an overdose, given
that prior research has suggested a relationship between
criminal justice involvement and overdose risk [3, 5, 23,
26–28]. Finally, we examine the relationship of overdose
experiences and justice involvement with naloxone
knowledge. Based on prior literature, we hypothesized
that we would identify subgroups with higher intensities
of involvement that could benefit from targeted OEND
due to their low naloxone awareness [23, 27–31]. We
also hypothesized that, consistent with prior research,
personally experiencing and witnessing an overdose




The analytic sample was drawn from a previously de-
scribed study of 817 adult (≥ 18 years) patients receiving
treatment for drug or alcohol use disorders in a residen-
tial addiction treatment program located in a suburban
area of Southeast Michigan during October 2014–Janu-
ary 2016 [35]. This facility served patients living
throughout Michigan and received client referrals
through contracts with the Michigan Department of
Corrections. The typical treatment duration for patients
was 60–90 days and patients were separated by gender.
Research assistants approached eligible patients (who
were aged ≥ 18 years and able to provide informed con-
sent) about their interest in completing a self-
administered survey to assess eligibility for enrollment
in a randomized controlled trial. Interested participants
provided informed consent, completed a paper and pen-
cil survey that took approximately 1 h to finish, and re-
ceived $5 for participating. This analysis uses data from
the cross-sectional survey and is not restricted to those
who participated in the randomized controlled trial. The
University of Michigan Institutional Review Board ap-
proved the study protocol.
We restricted the analytic sample to participants
whose treatment was prompted by the justice system
(excluded n = 40 participants), had used opioids (heroin
or prescription opioids not prescribed by a doctor) in
their lifetime (excluded n = 237 participants), and who
had non-missing responses to the measures described
below (excluded n = 26 participants, see Additional file 1:
Figure S1). Our analytic sample included 514 PWUO.
Measures
Justice involvement
We quantified participants’ cumulative and recent pre-
treatment justice system interactions using five items:
age at first arrest (median 18, range 9–59 years), number
of past-year arrests (median 1, range 0–42 arrests), num-
ber of lifetime arrests (mode 6–10, categories 1–2, 3–5,
6–10, 11–49, 50–99, or 100 or more arrests), number of
months during the past year spent in jail or prison (me-
dian 5.3, range 0–12 months), and lifetime number of
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years spent in jail or prison (median 3.5, range 0–
41.3 years). We formed categorical variables using quar-
tile or tertile breaks from distributions in the analytic
sample, with modifications when appropriate to enhance
interpretability (e.g., juvenile versus adult age at first ar-
rest). Categorical variables included age at first arrest
(9–17, 18–20, or 21–59 years), past-year arrests (0, 1–2,
3–42), lifetime arrests (1–5, 6–10, ≥ 11), past-year time
spent in jail or prison (0–1.9, 2–5.9, 6–10.9, 11–
12 months), and total time spent in jail or prison (0–0.9,
1–3.4, 3.5–7.4, 7.5–41.3 years).
Personal overdose experiences and witnessed overdose
Before answering questions, participants read the follow-
ing definition of an overdose: “The following questions
are about experiences with taking too much drugs or
medications/pills. This is sometimes called ‘poisoning,’
‘nodding out,’ or an ‘overdose’ or ‘OD.’” Participants re-
ported the number of overdoses experienced, timing of
their most recent overdose, and substances used during
the most recent overdose. Participants then read the def-
inition of a witnessed overdose: “The following questions
are about times you have seen someone else taking too
much drugs or medications/pills, and/or drinking too
much alcohol. This is sometimes called an ‘overdose.’
When someone has an overdose, they might have blue
skin color, convulsions, or difficulty breathing, lose con-
sciousness, collapse, cannot be woken up, or have a
heart attack or die.” [36] and reported the number of
overdoses they witnessed and drugs used by the victim
during the most recently witnessed overdose. We
formed binary variables for ever experiencing an over-
dose, experiencing an overdose in the past year, and ever
witnessing an overdose. We assessed the number of life-
time personal and witnessed overdoses as three-level
categorical variables (0, 1–5, or ≥ 6) and summarized
whether the participant’s most recent overdose experi-
ence and witnessed overdose involved heroin or pre-
scription opioids.
Covariates
Participants reported whether they had heard of nalox-
one and identified its purpose as an overdose treatment,
drug treatment for opioid dependence, detox, other, or
do not know (multiple responses were allowed). For the
analysis, we defined naloxone knowledge as having heard
of naloxone and correctly identifying its purpose as an
overdose treatment. We also examined demographic
characteristics, including age (18–29, 30–44, 45–
67 years), housing (dichotomized into temporary hous-
ing [rooming house/hotel, halfway house/group home,
inpatient treatment facility/hospital, jail, shelter, or
homeless] vs. stable housing [house/apartment or friend/
family member’s house]), education (less than high
school/GED or high school/GED or higher), race (black,
white, other, or multiple), and ethnicity (Hispanic vs.
non-Hispanic). We also summarized substance use char-
acteristics in several time frames, including lifetime and
past-year heroin and illicit prescription opioid use (de-
fined as use that was not as prescribed by a doctor).
Additionally, we summarized whether participants used
heroin for ≥ 7 consecutive days or injected any substance
in the month prior to entering treatment or jail. Finally,
we described nonmedical prescription opioid use in the
month before entering treatment or jail using four items
from the Current Opioid Misuse Measure found to de-
scribe nonmedical prescription opioid use in the addic-
tion treatment setting [37, 38]. Specifically, we
summarized whether participants reported engaging in
any of the following when using prescription opioids:
taking prescription opioids belonging to someone else,
borrowing prescription opioids from someone else, using
more than they were prescribed, or using prescription
opioids to treat symptoms other than pain.
Latent class analysis
Latent class measurement model
Latent class analysis (LCA) is a statistical technique used
to describe unobserved (i.e., latent) subgroups from pat-
terns of observed variables [39]. It is helpful for identifying
clusters (subgroups) of individuals who share patterns of
characteristics. Lorvick et al. previously described three
classes of justice involvement (low, medium, and high)
among women who used drugs in California based on
their incarceration history and community corrections in-
volvement [29]. We used LCA to identify subgroups of
criminal justice system involvement based on five categor-
ical variables: age at first arrest, past year arrests, lifetime
arrests, past year time spent in jail or prison, and total
time spent in jail or prison.
We fit LCA models with two to six classes and selected
the number of latent classes using a combination of inter-
pretability and model fit indices (Akaike information cri-
terion [AIC], Bayesian information criterion [BIC],
adjusted BIC, and entropy). Smaller values of the AIC and
BIC, and larger values of entropy indicate better relative
model fit [39]. After selecting the number of classes, we
ensured convergence to a globally optimal solution using
1000 random start values. Item response probabilities,
which reflect the distribution of each observed justice in-
volvement variable within each justice involvement class,
provided the basis for investigator-assigned class labels
used to describe each latent class. We completed LCA
analyses in SAS version 9.4 using PROC LCA [39].
Justice involvement by gender
Men and women have different criminal sentencing pat-
terns [40], and the relationship of offenses with drug-
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related mortality differs by gender [31]. Additionally,
men and women are treated separately in many residen-
tial addiction treatment programs, including the facility
where these data were collected. Therefore, we assessed
whether the justice involvement measurement model
operated similarly in groups defined by gender (men vs.
women). We fit the LCA model with and without con-
straints that required item response probabilities to be
equal by gender, testing the null hypothesis of measure-
ment invariance (i.e., that item response patterns were
the same for men and women) [39]. We used a likeli-
hood ratio test (LRT) to test for measurement invari-
ance. Rejecting the LRT (p < 0.05) implied that the
measurement model differed by gender.
Correlates of overdose experience, witnessed overdose,
and naloxone knowledge
We examined whether the prevalence of experiencing or
witnessing an overdose differed by justice involvement
class. We also assessed whether naloxone knowledge
was associated with ever experiencing or witnessing an
overdose or with justice involvement. We summarized
associations using bivariate and adjusted prevalence ra-
tios from quasi-Poisson regression models with robust
standard errors, an approach appropriate for highly
prevalent binary outcomes [41, 42]. Adjusted models in-
cluded sociodemographic characteristics (age, race,
housing status, education level) and substance use char-
acteristics (heroin use and injection drug use), as these
covariates could be associated with naloxone knowledge
or related outcomes and the main exposures for this
analysis (overdose, witnessed overdose, and justice in-
volvement) [5, 32, 33, 43, 44]. For regression analyses,
we formed a categorical justice involvement variable by
assigning participants to their most likely latent justice
involvement class (i.e., the modal class assignment
approach).
Sensitivity analyses
We conducted two sensitivity analyses. First, to assess
whether the relationships between justice involvement
and experiencing an overdose, witnessing an overdose,
and naloxone knowledge were robust to the modal class
assignment LCA approach, we used the pseudo-class
draws approach [45]. We conducted 20 imputations that
each assigned participants to a justice involvement class
based on LCA posterior probabilities [45]. We repeated
quasi-Poisson regressions for each imputed dataset for
all associations between justice involvement and over-
dose outcomes that reached statistical significance using
the modal class assignment approach and pooled results
using imputation procedures [46]. Second, to examine
whether our findings were similar among people who
had used opioids recently relative to when they entered
treatment, jail, or prison, we re-analyzed the relation-
ships between justice involvement, experiencing an over-
dose, and witnessing an overdose with naloxone
knowledge after restricting the sample to participants
who reported using heroin or prescription opioids not
prescribed to them in the past year and/or who reported
using prescription opioids nonmedically in the month
before entering treatment or jail.
Results
Participant characteristics
Most participants were white (74.7%), non-Hispanic
(95.3%), and aged 30–44 years (Table 1). Nearly half
were arrested for the first time as juveniles (47.9%). Most
were arrested once or twice in the year before treatment
or jail (41.6%) while 32.5% had no arrests. Participants
spent a median of 3.5 years in their lifetime and
5.3 months of the past year incarcerated.
Most participants had experienced (68.1%) and/or wit-
nessed (79.2%) an overdose, and 42.7% overdosed in the
past year. Only 56.2% of participants had naloxone
knowledge (62.1% had heard of naloxone and 90.6% of
those who had heard of it correctly identified it as an
overdose treatment).
Gender-stratified justice involvement LCA measurement
model
While the BIC indicated optimal fit for a three-class
justice involvement LCA model, the two-class model
had higher entropy, larger and more stable classes,
and was more interpretable than other models
(Table 2). Descriptive analysis suggested that justice
involvement characteristics differed by gender
(Table 1), and we rejected the null hypothesis of
measurement invariance using the LRT and the two
class model (χ2 = 72.0, degrees of freedom: 24, p value
< 0.05), implying that item response probabilities and
latent class interpretations differed by gender. There-
fore, we used the two-class gender-stratified model
for the remainder of analyses.
The gender-stratified model recovered two justice in-
volvement classes for each gender that we termed “high”
and “low” involvement (Fig. 1). Men with low justice in-
volvement (20.3% of men) had an older age at first arrest
(median 19, mean 22.2 years), few lifetime arrests (80.6%
had 1–5 arrests), and less incarceration time (lifetime
median 0.8, mean 1.2 years; past year median 4.0, mean
4.3 months); 72.2% had 1–2 arrests in the year before
treatment. Men with high justice involvement (79.7% of
men) were more commonly arrested for the first time as
a juvenile (65.3%), had more past year (median 8, mean
7.2 months), and lifetime incarceration time (median 6,
mean 8.3 years), and had more lifetime arrests (81.4%
had six or more lifetime arrests).
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Table 1 Sample description of 514 people who use opioids in justice diversion addiction treatment during 2014–2016 by gender
Total Women Men
n (%) n (%) n (%)
Total 514 (100) 151 (100) 363 (100)
Justice involvementa
Age at 1st arrest (years)
Missing 2 (0.4) 0 (0) 2 (0.6)
9–17 246 (47.9) 46 (30.5) 200 (55.1)
18–20 138 (26.9) 48 (31.8) 90 (24.8)
21–59 128 (24.9) 57 (37.8) 71 (19.6)
Median (IQR) 18 (16–20.5) 19 (17–22) 17 (15–19)
Lifetime arrests
Missing 0 (0) 0 (0) 0 (0)
1–5 173 (33.7) 61 (40.4) 112 (30.9)
6–10 171 (33.3) 49 (32.5) 122 (33.6)
11 or more 170 (32.1) 41 (27.2) 129 (35.5)
Arrests in year before treatment or jail
Missing 3 (0.6) 0 (0) 0 (0)
0 167 (32.5) 24 (15.9) 143 (39.4)
1–2 214 (41.6) 77 (51.0) 137 (37.7)
3–42 130 (25.3) 50 (33.1) 80 (22.0)
Median (IQR) 1 (0–3) 2 (1–3) 1 (0–2)
Time spent in jail or prison in lifetime (years)
Missing 7 (1.4) 4 (2.7) 3 (0.8)
0–0.9 107 (20.8) 66 (43.7) 41 (11.3)
1–3.4 135 (26.3) 47 (31.1) 88 (24.2)
3.5–7.4 134 (26.1) 23 (15.2) 111 (30.6)
7.5–41.3 131 (25.5) 11 (7.3) 120 (33.1)
Median (IQR) 3.5 (1–7.5) 1.1 (0.3–3) 5 (2.3–9.8)
Time spent in jail or prison in past year (months)
Missing 17 (3.3) 8 (5.3) 9 (2.5)
0–1.9 119 (23.2) 43 (28.5) 76 (20.9)
2–5.9 134 (26.1) 59 (39.1) 75 (20.7)
6–10.9 125 (24.3) 28 (18.5) 97 (26.7)
11–12 119 (23.2) 13 (8.6) 106 (29.2)
Median (IQR) 5.3 (2–10) 3.1 (1.4–6) 6.5 (2.9–12)
Overdose experience
Experienced an overdose 350 (68.1) 114 (75.5) 236 (65.0)
Most recent overdose involved heroin and/or prescription opioidsb 254 (72.6) 87 (76.3) 167 (70.8)
Experienced an overdose in the year before treatment 219 (42.7) 83 (55.0) 136 (37.5)
Number of experienced overdoses in lifetime
0 164 (31.9) 37 (24.5) 127 (35.0)
1–5 225 (43.8) 63 (41.7) 162 (44.6)
6 or more 125 (24.3) 51 (33.8) 74 (20.4)
Witnessed overdose
Witnessed any overdose 407 (79.2) 127 (84.1) 280 (77.1)
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The defining features and item response probabilities
among women differed from men. Women with low just-
ice involvement (46.5% of women) were more likely to be
arrested at an older age at first arrest (84.2% aged ≥
18 years), had few lifetime arrests (75.7% with 1–5 arrests),
and spent less time incarcerated (lifetime median 0.3,
mean 0.5 years; past year median 2.6, mean 2.8 months).
Women with high justice involvement (53.5% of women)
were younger at their first arrest (70.3% < 21 years), had
more lifetime arrests (50.6% had ≥ 11 arrests), and spent
more time incarcerated (lifetime median 4.4, mean
2.9 years; past year median 4, mean 5.4 months).
Table 1 Sample description of 514 people who use opioids in justice diversion addiction treatment during 2014–2016 by gender
(Continued)
Total Women Men
n (%) n (%) n (%)
Most recently witnessed overdose involved
heroin and/or prescription opioidsc
339 (83.3) 117 (92.1) 222 (79.3)
Number of witnessed overdoses in lifetime
0 107 (20.8) 24 (15.9) 83 (22.9)
1–5 269 (52.3) 84 (55.6) 185 (51.0)
6 or more 138 (26.9) 43 (28.5) 95 (26.2)
Naloxone knowledge
Heard of naloxone 319 (62.1) 109 (66.9) 210 (57.9)
Identified purpose of naloxoned 289 (90.6) 101 (92.7) 188 (89.5)
Demographic and social characteristics
Age (years), Median (IQR) 34 (27–46) 31 (26–40) 36 (28–48)
Race
Black 83 (16.2) 18 (11.9) 65 (17.9)
White 384 (74.7) 116 (76.8) 268 (73.8)
Other 13 (2.5) 3 (2.0) 10 (2.8)
Multiple races 34 (6.6) 14 (9.3) 20 (5.5)
Hispanic ethnicity 24 (4.7) 5 (3.3) 19 (5.2)
Less than high school education/GED 83 (16.2) 54 (14.9) 29 (19.2)
Temporary housing in past 3 monthse 290 (56.4) 77 (51.0) 213 (58.7)
Substance use
Lifetime heroin use 347 (67.5) 117 (77.5) 230 (63.3)
Heroin use in the past yearf 249 (71.9) 93 (79.5) 156 (67.8)
Used heroin ≥ 7 consecutive days during the month
before treatment or jailf
194 (55.9) 70 (59.8) 124 (53.9)
Lifetime prescription opioid use (not as prescribed a doctor) 485 (94.4) 144 (95.4) 341 (93.9)
Used prescription opioids in the past year (not as prescribed
by a doctor)g
271 (55.9) 96 (66.7) 175 (51.3)
Took or borrowed prescription opioids belonging to someone
else, took more than prescribed, or used for reasons other
than for pain management
371 (72.2) 118 (78.1) 253 (70.0)
Injected drugs in the month before entering treatment or jail 221 (43.0) 75 (49.7) 146 (40.2)
aLatent class analysis allows for missing values in indicators and uses information on available indicators to create classes for participants with missing data.
Therefore, totals for justice involvement may not add to the full sample size
bAmong those who experienced an overdose. Includes most recent experienced overdose events where the participant reported they used heroin and/or
prescription opioids. An additional 7 participants (5 men, 2 women) did not report substances used
cAmong those who witnessed an overdose. Includes most recently witnessed overdose events where the participant reported that the victim used heroin and/or
prescription opioids. An additional 9 participants (6 men, 3 women) did not know or did not report substances used by the victim
dAmong those who had heard of naloxone
eIncludes living in a halfway house or group home, inpatient facility, jail, shelter, or homeless
fAmong those who used heroin in their lifetime. An additional 16 participants (10 men, 6 women) reported lifetime heroin use but declined to answer questions about
past year heroin use. An additional 5 participants (4 men, 1 woman) declined to answer questions about use in the 30 days before entering treatment or jail
gAmong those who used prescription opioids in their lifetime. An additional 19 participants (14 men, 5 women) reported lifetime prescription opioid use but
declined to answer questions about past year prescription opioid use
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Correlates of overdose and naloxone knowledge
We found no differences in prevalence of experiencing
or witnessing an overdose by justice involvement in bi-
variate analyses (Fig. 2). Experiencing an overdose and
witnessing an overdose were both positively associated
with naloxone knowledge among men and women
(Fig. 3). Only 26.0% of men who had never experienced
an overdose were knowledgeable of naloxone, whereas
65.7% of men with lifetime overdose experience had na-
loxone knowledge. Among women, 35.1% of women
who had not overdosed had naloxone knowledge vs.
77.3% who overdosed had naloxone knowledge. High
justice involvement was associated with lower naloxone
knowledge among men in bivariate analyses.
Men who experienced an overdose in their lifetime
were 50% more likely to have naloxone knowledge
than men who had not experienced an overdose after
adjustment for age, race, education level, residence in
temporary housing, lifetime heroin use, and injection
drug use in the 30 days before treatment (PR [95%
CI] 1.5 [1.1–2.0]). Women who experienced an over-
dose (PR [95% CI] 1.5 [0.95–2.4], p = 0.08) or wit-
nessed an overdose (PR [95% CI] 1.4 [0.97–2.1], p =
0.07) in their lifetime were marginally more likely to
have naloxone knowledge. Naloxone knowledge
among men did not differ by justice involvement after
adjustment (PR [95% CI] 0.98 [0.79–1.2]).
Sensitivity analyses
Assigning justice involvement classes with multiple imput-
ation (i.e., the pseudo-class approach) yielded similar re-
sults to modal class assignment. The bivariate association
of justice involvement with naloxone knowledge among
men was not statistically significant after multiple imput-
ation (PR [95% CI] 0.79 [0.61–1.0], p = 0.08).
After restricting the analytic sample to participants
who reported using heroin or prescription opioids not
Table 2 Fit of latent classes models of justice involvement
among a sample of people who use opioids in justice diversion
addiction treatment during 2014–2016 (n = 514)
Classes Log likelihood AIC BIC Adjusted BIC Entropy
2 − 2897.1 595.7 701.7 622.4 0.82
3 − 2852.7 532.9 694.1 573.5 0.69
4 − 2841.6 536.7 753.0 591.1 0.71
5 − 2822.0 523.5 795.0 591.8 0.73
6 − 2809.3 524.1 850.8 606.4 0.73
Italic font indicates optimal fit index value of the tested solutions
Fig. 1 Patterns of justice involvement among men and women who use opioids in justice diversion addiction treatment during 2014–2016 (n =
363 men and 151 women). Two justice involvement classes per gender were identified among a sample of 514 PWUO in justice diversion
addiction treatment. Men with low involvement (20.3% of men) were arrested for the first time at an older age and arrested more often in the
past year. Men with high involvement (79.7%) had more arrests and incarceration time. Similar classes emerged among women, but women had
more past year arrests and spent less time incarcerated than men. Women with low involvement comprised 46.5% of the sample and high
involvement was slightly more common (53.5%)
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prescribed to them in the past year and/or who re-
ported using prescription opioids nonmedically in the
month before entering treatment or jail, 423 partici-
pants (288 men, 135 women) remained for analysis.
Men who experienced an overdose remained more
likely to have naloxone knowledge in adjusted analysis
(PR [95% CI] 1.5 [1.1–2.2], Additional file 1: Table
S1). The marginal relationships of experiencing and
witnessing an overdose among women were no longer
present.
Discussion
The primary finding of this study was that nearly all
PWUO receiving treatment at this residential justice di-
version addiction treatment facility during 2014–2016
had experienced and/or witnessed an overdose, but only
half had heard of naloxone and correctly identified it as
an overdose treatment. Thus, PWUO receiving treat-
ment at this facility are appropriate candidates for
OEND given their high likelihood of witnessing or ex-
periencing an overdose after treatment completion [3,
Fig. 2 Prevalence of experiencing and witnessing an overdose among people who use opioids in justice diversion addiction treatment during
2014–2016 (n = 363 men and 151 women). Prevalence of experiencing and witnessing an overdose was high across justice involvement groups
in both genders. Prevalence of overdose outcomes did not differ by justice involvement history
Fig. 3 Associations of overdose experience, witnessing an overdose, and justice involvement with naloxone knowledge among men and women
who use opioids in justice diversion addiction treatment during 2014–2016. Prevalence of naloxone knowledge was higher men who had
experienced an overdose in their lifetime (adjusted prevalence ratio [aPR, 95% confidence interval, CI] men: 1.5 [1.1–2.0]) and marginally higher
among women who had experienced an overdose (aPR [95% CI] 1.5 [0.95–2.4]). Women who had witnessed an overdose were also marginally
more likely to have naloxone knowledge (aPR [95% CI] 1.4 [0.97–2.1]). There was no difference in prevalence of naloxone knowledge for men or
women by their justice involvement history (aPR [95% CI] men 0.98 [0.82–1.2, women 0.97 [0.79–1.2]). Among men, there was also no difference
in naloxone knowledge by history of witnessing an overdose (aPR [95% CI] 1.1 [0.89–1.5]). Adjusted prevalence ratios are adjusted for age, race,
education level, residence in temporary housing (defined as reporting living in a halfway house or group home, inpatient facility, jail, shelter, or
homeless), lifetime heroin use, and injection drug use in the 30 days prior to treatment. Ref reference group
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5]. Justice involvement was not associated with naloxone
knowledge or with overdose experiences, either person-
ally or as a witness. These findings suggest that clients
in justice diversion residential treatment programs in
Michigan may be candidates for diversion-based OEND,
regardless of their path to treatment. Future work could
examine whether OEND scale-up in diversion-based
treatment facilities elsewhere should be similarly gener-
alized to all clients or focus on particular PWUO or
other subgroups receiving treatment.
In light of continued increases in overdose mortality,
the US Surgeon General recently highlighted a need for
comprehensive addiction treatment services in jails and
prisons and a focus on criminal justice reforms that im-
prove the health of PWUO [1, 2, 11]. We identified two
subgroups of PWUO that were defined by simultan-
eously examining several aspects of their justice involve-
ment history using LCA. These subgroups reflected two
pathways that men and women were diverted to treat-
ment in Michigan. Most men (80%) had long-term just-
ice involvement, whereas few were diverted after many
recent arrests, likely to avoid incarceration. Women had
had more past year arrests and spent less time incarcer-
ated than men. High and low justice involvement was
equally common among women. The patterns of justice
involvement in this study reflect both justice involve-
ment patterns among all PWUO and the selection
process for diversion programs, such as the one where
this study was conducted. For criminal justice reforms
to decrease post-incarceration overdose mortality, there
is both a need to incorporate OEND into the justice di-
version addiction treatment setting and to assess
whether current policies divert PWUO at highest risk of
returning to opioid use and overdosing after treatment.
Whether current diversion program eligibility criteria
exclude PWUO at highest risk of post-incarceration
overdose given, for example, many recent arrests, is
unknown.
The prevalence of experiencing and witnessing an
overdose in our study approached the maximum esti-
mates reported in a 2015 systematic review (i.e., 50–96%
of people who use illicit drugs witness an overdose and
17–68% personally experience an overdose) [5]. The fact
that just over half of participants had heard of naloxone
and identified it as an overdose treatment, demonstrat-
ing lower awareness than has been documented in prior
studies [32, 43, 44, 47], highlights the need for the edu-
cational component of OEND in this setting. Naloxone
knowledge was particularly low among male participants
who had never personally experienced an overdose. Re-
sults from prior research describing the relationship be-
tween personally experiencing an overdose and naloxone
knowledge and carrying naloxone have been mixed [32,
48], though one study characterized an association
between personal concern for overdose risk and accept-
ing a supply of naloxone in the emergency department
[33] and qualitative evidence suggests that PWUO may
learn about naloxone from emergency medical providers
who respond when they experience an overdose [34].
While we cannot comment on whether these individuals
experienced an overdose post-treatment, the fact that
they were in addiction treatment, had used opioids, and
had no knowledge of naloxone implies that they would
benefit from OEND during incarceration or treatment.
We found no differences in prevalence of experiencing
or witnessing an overdose or in naloxone knowledge by
justice involvement, supporting that OEND should be
provided to all PWUO in justice diversion addiction
treatment.
Our study has several strengths. The LCA approach
allowed for a synthesis of several aspects of justice in-
volvement simultaneously. The two groups that emerged
were not evident when we examined each justice in-
volvement indicator in isolation. We also had a large
sample of PWUO diverted to addiction treatment at sev-
eral stages post-arrest, which encompassed a variety of
potential clients eligible for justice diversion addiction
treatment. Another benefit of the large sample size was
our ability to stratify our analysis by gender.
Our findings are not without limitation. We studied
participants from a single addiction treatment facility lo-
cated in a suburban area of the mid-Western US and all
received treatment because of their criminal justice sys-
tem involvement. The prevalence of naloxone know-
ledge, experiencing an overdose, and witnessing an
overdose may reflect levels of OEND implementation
specific to the Midwest and may not be generalizable
outside this region, given that the availability of OEND
and other harm reduction services is known to vary geo-
graphically [49, 50]. We were unable to determine when
clients were diverted relative to the time they committed
the crimes preempting treatment and cannot comment
on specific differences between those diverted after ar-
rest, incarceration, or parole/probation. Given the vari-
ability in diversion programs, it is difficult to determine
whether the patterns of justice involvement observed
here would extend to other states [19]. Our ability to
evaluate whether our results reflect trends in justice in-
volvement in non-diverted PWUO is limited by the lack
of published criteria for diversion program eligibility.
This lack of objective criteria further limited our ability
to disentangle the sources of gender and other dispar-
ities (e.g., by race) in diversion.
Our study relied on self-reported characteristics from
the pre-treatment period, potentially introducing recall
biases. The cross-sectional design limited our ability to
define the temporal sequence of events (e.g., whether in-
dividuals experienced or witnessed overdoses after their
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involvement with the criminal justice system). We had
no information about participants’ access to or experi-
ence with syringe services programs or other harm re-
duction programs or how long they had used opioids,
both of which may impact their familiarity with nalox-
one. Our results may not be generalizable to persons
who misused their own prescription opioids as we re-
stricted the analytic sample to participants who self-
reported ever using opioids (heroin or prescription opi-
oids not prescribed by a doctor), which may have low
sensitivity to misuse of one’s own prescribed opioids [51,
52]. Finally, although we had an appropriately high en-
tropy (> 0.8) to assign individuals to their most probable
justice involvement class, this approach may have under-
estimated the magnitude of associations between justice
involvement with overdose, witnessed overdose, and na-
loxone knowledge [53–55].
Conclusions
The low prevalence of naloxone knowledge and high
prevalence of experiencing and witnessing an overdose
in our sample of PWUO suggests that OEND should be
routinely incorporated into justice diversion addiction
treatment. Further, OEND should be provided to all cli-
ents, regardless of pre-treatment overdose experience or
justice involvement characteristics.
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